-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

627.O2.6 627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications

Symposia: Aggressive Lymphomas: Pharmacologic Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Combination therapy, Lymphomas, Bispecific Antibody Therapy, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Treatment Considerations, Biological therapies, Immunotherapy, Aggressive lymphoma, Lymphoid Malignancies, Technology and Procedures, Study Population, Human, Profiling
Monday, December 9, 2024: 2:45 PM-4:15 PM
Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)
Moderators:
Muhit Ozcan, MD, and Christopher Melani, MD, National Cancer Institute, National Institutes of Health
Disclosures:
No relevant conflicts of interest to declare.

This session focuses on novel monotherapies and some novel combinations in rare diseases for aggressive lymphomas.
2:45 PM

Michael J. Dickinson, MBBS, DMedSci1, Carmelo Carlo-Stella, MD2, Franck Morschhauser, MD, PhD3, Emmanuel Bachy, MD, PhD4, Guillaume Cartron, MD, PhD5*, Paolo Corradini, MD6, Nancy L. Bartlett, MD7, Gloria Iacoboni, MD8*, Cyrus Khan9*, Mark S. Hertzberg, MBBS10, Lorenzo Falchi, MD11, Joshua Brody, MD12*, Marek Trněný, MD, CSc13, Estefania Mulvihill14*, Aurelien Berthier14, Alessia Bottos, PhD14*, James Relf15*, Fabiola Bene Tchaleu16*, Linda Lundberg14* and Martin Hutchings, MD, PhD17

1Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia
2Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
3Hôpital Claude Huriez and CHU de Lille, Lille, France
4Centre Hospitalier Lyon Sud, Pierre-Bénite, France
5CHU de Montpellier, Montpellier, France
6University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
8Vall d’Hebron University Hospital, Barcelona, Spain
9Allegheny Health Network, Pittsburgh, PA
10Prince of Wales Hospital and University of New South Wales, Sydney, Australia
11Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
12Tisch Cancer Institute, New York, NY
13Charles University, Prague, Czech Republic
14F. Hoffmann-La Roche Ltd, Basel, Switzerland
15Roche Products Ltd, Welwyn Garden City, United Kingdom
16Genentech, Inc., South San Francisco, CA
17Rigshospitalet, Copenhagen, Denmark

3:00 PM

Matthew Matasar, MD, MS1, Max S. Topp2*, John N. Allan, MD3, Stephen M. Ansell, MD, PhD4, Jeffrey A. Barnes, MD, PhD5*, Jon E. Arnason, MD6, Jean-Marie Michot7*, Neta Goldschmidt8*, Susan M. O'Brien9, Uri Abadi, MD10,11*, Irit Avivi Mazza12*, Jingxian Cai13*, Julia Zecchini13, Min Zhu13*, Jurriaan Brouwer-Visser13, Aafia Chaudhry13, Hesham Mohamed13, Srikanth Ambati13 and Jennifer L. Crombie, MD14

1Division of Blood Disorders, Rutgers Cancer Institute and RWJBarnabas Health, New Brunswick, NJ
2Universitätsklinikum Würzburg, Würzburg, Germany
3Weill Cornell Medicine, New York, NY
4Mayo Clinic, Rochester, MN
5Massachusetts General Hospital Cancer Center, Boston, MA
6Beth Israel Deaconess Medical Center, Boston, MA
7Gustave Roussy Cancer Campus, Villejuif, France
8Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
9Chao Family Comprehensive Cancer Center, UC Irvine Medical Center, Orange, CA
10Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
11Meir Medical Center, Kfar Saba, Israel
12Ichilov University Hospital, Tel-Aviv, Israel
13Regeneron Pharmaceuticals, Inc., Tarrytown, NY
14Dana-Farber Cancer Institute, Boston, MA

3:15 PM

Franck Morschhauser, MD, PhD1, David Belada, MD, PhD2, Johannes Duell, MD3*, Wojciech Jurczak, MD, PhD4, Tae Min Kim, MD, PhD5*, Won Seog Kim, MD, PhD6*, Takahiro Kumode, MD, PhD7*, Javier López Jiménez, MD8*, Caressa Meert, MD9*, Sergio Ortegon Alcaide, MD10*, Catherine Thieblemont, MD11, Yajian Jiang, MD, PhD12, Mina Khoshdeli, PhD13*, Yanli Wang, MS13*, Evelyn Guo13*, Daniela Hoehn, MD, PhD13* and Sherida Woei-A-Jin, MD, PhD14*

1University of Lille, CHU Lille, Lille, France
24th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
3Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
4MSC National Research Institute of Oncology, Kraków, Poland
5Seoul National University Hospital, Seoul, Korea, Republic of (South)
6Samsung Medical Center, Seoul, Korea, Republic of (South)
7Department of Hematology and Rheumatology, Kindai University, Osaka, Japan
8Servicio de Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, Madrid, Spain
9Algemeen Ziekenhuis Delta, Roeselare, Belgium
10Hospital Universitario Virgen Macarena, Sevilla, Spain
11Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France
12AbbVie, North Chicago, IL
13Genmab, Plainsboro, NJ
14Department of General Medical Oncology, Universitair Ziekenhuis Leuven, Leuven, Belgium

3:30 PM

Sameh Gaballa, MD1, Jing-Zhou Hou, MD, PhD2, Sumana Devata, MD3, Seok-Goo Cho4*, Ranjit Nair, MD5, Dok Hyun Yoon, MD, PhD6, Ryan Jacobs7, Koji Izutsu, MD, PhD8, Don A. Stevens, MD9, Dai Maruyama, MD, PhD10, Constantine S. Tam, MD, MBBS11, Yazeed Sawalha, MD12, Aravind Ramakrishnan, MD13, Matthew Matasar, MD, MS14, Denise Brennan15*, Sue Zhu15*, Robin Lesley, PhD16*, Yasuhiro Oki, MD16, David Sermer17* and Tae Min Kim, MD, PhD18*

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2Lemieux Center for Blood Cancers, UPMC Hillman Cancer Center, Pittsburgh, PA
3Medical College of Wisconsin, Milwaukee, WI
4Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
5The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
7Atrium Health Levine Cancer Institute, Charlotte, NC
8National Cancer Center Hospital, Tokyo, Japan
9Norton Cancer Institute, Norton Health Care, Louisville, KY
10Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
11Alfred Hospital and Monash University, Melbourne, VIC, Australia
12The Ohio State University Comprehensive Cancer Center, Columbus, OH
13Sarah Cannon Transplant and Cellular Therapy, St. David’s South Austin Medical Center, Austin, TX
14Rutgers Cancer Institute, New Brunswick, NJ
15AstraZeneca, Waltham, MA
16AstraZeneca, South San Francisco, CA
17AstraZeneca, New York, NY
18Seoul National University Hospital, Seoul, Korea, Republic of (South)

3:45 PM

Jean-Marie Michot, MD1*, Franck Morschhauser, MD, PhD2, Silvia Ferrari, MD3*, Judit Mészáros Jørgensen, MD, PhD4*, Loretta Nastoupil5*, Emmanuel Bachy, MD, PhD6, Michael Pourdehnad, MD7, Akshay Sudhindra, MD8, Alev Akyol, MD9*, Bérengère de Moucheron, PharmD10*, Soraya Carrancio, PhD11*, Jessica Voetsch, PhD12*, Xirong Zheng, PhD13* and Julio C. Chavez, MD14

1Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Institute of Cancer, Villejuif, France
2University of Lille, Lille, FRA
3ASST Papa Giovanni XXIII, Bergamo, Italy
4Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
5Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
6Lyon Sud Hospital, Lyon, France
7Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb, San Francisco, CA
8Late Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb, Madison, NJ
9Bristol Myers Squibb, Princeton, NJ
10Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain
11Oncogenesis (ONC) Thematic Research Center (TRC), Bristol Myers Squibb, San Diego, CA
12Translational Informatics and Predictive Sciences, Bristol Myers Squibb, Lawrence Township, NJ
13Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Princeton, NJ
14Department of Malignant Hematology, University of South Florida/Moffitt Cancer Center, Tampa, FL

4:00 PM

Ariela Noy, MD1, Stefan K. Barta, MD2, Deukwoo Kwon, PhD3*, Robert Baiocchi, MD, PhD4, Juan Carlos Ramos, MD5, Paul Rubinstein, MD6*, Amy Chadburn, MD7 and Richard F. Ambinder, MD8,9

1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Abramson Cancer Center, The Fox Chase Cancer Center Foundation, Philadelphia, PA
3Icahn School of Medicine at Mount Sinai, New York, NY
4Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
5Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
6Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL
7Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
8Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
9Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

*signifies non-member of ASH